Price (delayed)
$69.98
Market cap
$7.42B
P/E Ratio
55.1
Dividend/share
N/A
EPS
$1.27
Enterprise value
$7.34B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
There are no recent dividends present for CORT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.